Valneva SE ADR (VALN)
NASDAQ: VALNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VALN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $490.86M
- Forward P/E
- 4.34
- EPS (TTM)
- -$2.10
- Dividend yield
- None
- 52-week range
- 4.75 – 12.18
- Day range
- 5.12 – 5.30
- Volume / Avg
- 17.55K / 23.10K
- Beta
- —
- Shares outstanding
- 95.13M
- Next earnings
- Nov 24, 2026
52-week range
VALN stock today
Shares of Valneva (VALN) finished lower on Nov 20 at $5.16, a drop of 3.82% or $0.205 per share, versus the S&P 500's 3.70% decline. Shares are 57.6% below their 52-week high of $12.18, set on Feb 24, 2026 and 8.6% above the 52-week low of $4.75, near the bottom of the past year's range. VALN is down 41.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.1%.
Valneva has posted a net loss over the last twelve months (EPS of -$2.10), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 24 before the market opens; analysts expect EPS of -$0.23.
Summary generated from market data by MetaCap's automated system. Methodology
About Valneva
Company profileValneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Thomas Lingelbach
- Headquarters
- Saint-Herblain
- Employees
- 620
- IPO year
- 2021
- Website
- valneva.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$12.28+137.98%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 24, 2026
- EPS estimate
- $-0.23
VALN news
All VALN news- Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQNasdaqVALN, BRK.A
- Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®GlobeNewswire
- Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®GlobeNewswire
- Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2NasdaqVALN, MOG.A
- Valneva publiera ses résultats financiers consolidés des neuf premiers mois de l’année le 24 novembre 2026GlobeNewswire
- Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026GlobeNewswire
- Valneva présentera ses activités et rencontrera les investisseurs lors de prochaines conférences santé aux États-Unis et en EuropeGlobeNewswire
- Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesGlobeNewswire
Valneva peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs VALN |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs VALN |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs VALN |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs VALN |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs VALN |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs VALN |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs VALN |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs VALN |
Indexes, lists and sector
Valneva stock FAQ
What is Valneva's stock price today?
VALN last traded at $5.16 as of Nov 20, 4:00 PM EST, down 3.82% on the day. Prices are delayed at least 15 minutes.
When is Valneva's next earnings date?
Valneva is expected to report earnings on Tuesday, November 24, 2026. Analysts expect EPS of $-0.23.
Who is Valneva's CEO?
Mr. Thomas Lingelbach is the chief executive officer of Valneva SE ADR, which has about 620 employees.
What is the VALN 52-week high?
The 52-week high for VALN is $12.18 and the 52-week low is $4.75. The stock is currently 57.6% below its high.